Coverage / AMGN / Trade Card

AMGN

Amgen Inc

BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 467.06 Healthcare - Drug Manufacturers - GeneralREDUCE ZONE
ACTIONABLEMethodology gates passed
69

Position levels

Currenttoday
USD 467.06
Buy <=wait / entry
USD 336.67
Trim >=take some off
USD 410.00
Thesis breakA materially negative MariTide Phase III efficacy or tolerability readout, or a ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case37%100 / 10037.0
Base case50%62 / 10031.0
Bear case13%10 / 1001.3
Weighted conviction69 / 100 - BUY

Top risks

  • Q2 2026 earnings beat with revenue $10.05B (+10% YoY) and raised full-year 2026 guidance to $38.2B-$39.4B revenue and $15.80-$17.08 GAAP EPS
  • Six key growth drivers grew 26% YoY generating nearly 70% of Q2 product sales; 22 products with double-digit growth
  • Positive late-stage trial results for experimental autoimmune drug meeting primary endpoint and landmark clinical results for IMDELLTRA and TEZSPIRE
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n